Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

image for article on ovarian cancer prevention vaccine

Scientists in the U.K. developing world’s first vaccine to prevent ovarian cancer

OvarianVax, in development at the University of Oxford, has just received up to £600,000 from Cancer Research U.K. to pursue the world’s first vaccine designed to prevent ovarian cancer before it begins. The idea is to train the immune system to recognize over 100 proteins found on early-stage ovarian cancer cells, then destroy those cells before they can spread. For women carrying BRCA gene mutations, who currently face the wrenching choice of preventive surgery that ends fertility and triggers early menopause, a vaccine could transform what’s possible. It’s still early days, with lab work and clinical trials ahead, but the project signals a real shift in cancer research: moving from treatment toward prevention, and giving high-risk women better options worldwide.

A close-up of a medical syringe and insulin vial for an article about stem cell therapy for type 1 diabetes, for article on stem cell therapy type 1 diabetes

Chinese researchers reverse type 1 diabetes using a patient’s own stem cells

Type 1 diabetes reversal using a patient’s own stem cells marks a historic milestone in medicine. A 25-year-old woman in China received a transplant of insulin-producing cells reprogrammed from her own body, and within three months was generating insulin naturally — eventually eliminating her need for external injections entirely. Published in Cell in 2024, the research is significant because it bypasses donor tissue and immunosuppressant drugs entirely, dramatically reducing rejection risk. For the roughly 8.4 million people worldwide living with type 1 diabetes, this proof of concept offers a genuinely new direction for treatment.

Medical researcher in a lab examining vials related to asthma and COPD treatment and mRNA vaccine development, for article on benralizumab injection, for article on mRNA lung cancer vaccine

World’s first mRNA lung cancer vaccine enters human trials in seven countries

A landmark mRNA lung cancer vaccine is now being tested in human patients for the first time, marking a historic milestone in cancer treatment. BNT116, developed by BioNTech, uses the same messenger RNA technology behind COVID-19 vaccines to train the immune system to recognize and destroy non-small cell lung cancer cells. The phase 1 trial spans 34 sites across seven countries, with roughly 130 patients enrolled. Unlike chemotherapy, this approach targets only tumor cells, potentially offering a more precise and lasting defense against the world’s deadliest cancer, which kills 1.8 million people annually.

Seastar

Lab-grown starfish released into wild for the first time ever, saving species from extinction

Due to sea star wasting disease, lower oxygen levels in seawater, and rising temperatures, starfish populations are at risk around the globe. Across the last decade, the sunflower star population plummeted by over 90%. Fortunately, in 2019, marine biologist Jason Hodin stepped up to save the sea stars from extinction. At the University of Washington’s Friday Harbor Labs, Hodin has carefully grown and raised several generations of sunflower starfish in a controlled environment, breeding them from a select sample of starfish he rescued from the harbor five years prior.

Mt. Everest

Chinese drones to transport trash from Nepal’s Mount Everest

Nepal is set to deploy Chinese-made drones to transport garbage from the slopes of Everest, marking the first time unmanned aerial vehicles (UAVs) will be used commercially in the country’s high-altitude zones. This initiative announced by China’s leading drone manufacturer, Da Jiang Innovations aims to reduce the risks faced by Sherpas and improve waste management on the world’s tallest peak.

Vials of blood

U.S. Food and Drug Administration approves blood test to screen for colon cancer

The test, known as Shield, isn’t meant to replace colonoscopies, but is generating enthusiasm among doctors who say it has the potential to boost the dismal rate of screenings for the second-highest cause of cancer death in the United States. Shield has previously been available to doctors as a screening tool, at an out-of-pocket cost of $895. With the FDA approval, Medicare and private insurance companies are much more likely to cover the cost of the blood test, making it more widely accessible for patients.

Fervo Energy geothermal plant, for article on enhanced geothermal power purchase agreement

World’s biggest geothermal power purchase agreement completed in western U.S.

A Utah geothermal project just secured what developers are calling the world’s largest geothermal power purchase agreement — a 15-year deal to deliver 320 megawatts of always-on clean electricity to Southern California Edison, enough to power roughly 350,000 homes. Fervo Energy’s Cape Station plant uses horizontal drilling borrowed from the oil and gas industry to circulate water through deep hot rock, unlocking geothermal power in places where it was never viable before. First electrons are expected to flow in 2026, with the rest coming online by 2028. For a clean grid that needs to run when the sun sets and the wind stops, this kind of steady, weather-proof power may be the missing piece — and a signal that geothermal is ready for prime time.

Good news for public health, for article on CAB-LA HIV prevention, for article on lenacapavir HIV prevention

New twice-yearly shot to prevent HIV achieves 100% success rate in late-stage trial

Lenacapavir, a twice-yearly HIV prevention shot, protected every single one of 2,134 women who received it in a late-stage trial across South Africa and Uganda — a 100% efficacy result so striking that monitors ended the blinded phase early. The breakthrough matters because daily prevention pills, while powerful in theory, often falter in real life: stigma, forgotten doses, and disrupted routines all chip away at protection. Two clinic visits a year, by contrast, means a full year of coverage. The remaining hurdle is access, with advocates pressing manufacturer Gilead to license generic versions for the regions hardest hit. If that happens, a tool this effective could reshape the global push to end the HIV epidemic by 2030.

Mouse

Japanese scientists reverse Alzheimer’s synapse damage in mice

Scientists from the Okinawa Institute of Science and Technology say they have reversed the signs of Alzheimer’s disease in lab mice by restoring the healthy function of synapses, critical parts of neurons that shoot chemical messages to other neurons. If the treatment successfully survives the gauntlet of clinical studies with human participants, it could potentially lead to a groundbreaking new treatment for humans suffering from the deadly disease.